BDX – Becton, Dickinson and Company
Float Short %
1.47
Margin Of Safety %
11
Put/Call OI Ratio
0.3
EPS Next Q Diff
-0.59
EPS Last/This Y
9.11
EPS This/Next Y
0.97
Price
193.96
Target Price
197.11
Analyst Recom
2.29
Performance Q
1.24
Relative Volume
0.9
Beta
0.24
Ticker: BDX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | BDX | 181.68 | 0.70 | 0.96 | 17617 |
| 2025-11-11 | BDX | 189.04 | 0.71 | 1.52 | 17737 |
| 2025-11-12 | BDX | 192.15 | 0.71 | 0.92 | 17821 |
| 2025-11-13 | BDX | 193.08 | 0.71 | 0.92 | 18078 |
| 2025-11-14 | BDX | 193.06 | 0.71 | 0.67 | 18296 |
| 2025-11-17 | BDX | 191.03 | 0.70 | 0.67 | 18601 |
| 2025-11-18 | BDX | 192.34 | 0.69 | 0.47 | 18896 |
| 2025-11-19 | BDX | 191.27 | 0.68 | 0.26 | 19008 |
| 2025-11-20 | BDX | 189.54 | 0.68 | 0.11 | 19078 |
| 2025-11-21 | BDX | 192.72 | 0.66 | 0.08 | 19348 |
| 2025-11-24 | BDX | 190.99 | 0.63 | 0.09 | 16236 |
| 2025-11-25 | BDX | 195.44 | 0.61 | 0.24 | 16517 |
| 2025-11-26 | BDX | 193.91 | 0.60 | 0.15 | 16860 |
| 2025-12-01 | BDX | 191.87 | 0.59 | 0.15 | 17158 |
| 2025-12-02 | BDX | 190.44 | 0.58 | 0.22 | 17334 |
| 2025-12-03 | BDX | 193.59 | 0.58 | 0.45 | 17371 |
| 2025-12-04 | BDX | 193.86 | 0.58 | 0.02 | 17375 |
| 2025-12-05 | BDX | 193.97 | 0.30 | 0.06 | 28094 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | BDX | 181.64 | 2.7 | 570.3 | 14.37 |
| 2025-11-11 | BDX | 189.02 | -18.1 | 613.5 | 14.93 |
| 2025-11-12 | BDX | 192.14 | -18.1 | 560.1 | 14.93 |
| 2025-11-13 | BDX | 193.06 | -18.1 | 534.0 | 14.93 |
| 2025-11-14 | BDX | 193.01 | -18.1 | 522.7 | 14.93 |
| 2025-11-17 | BDX | 191.01 | -18.1 | 499.2 | 14.93 |
| 2025-11-18 | BDX | 192.31 | -18.1 | 538.7 | 14.93 |
| 2025-11-19 | BDX | 191.22 | -18.1 | 510.0 | 14.93 |
| 2025-11-20 | BDX | 189.55 | -18.1 | 503.2 | 14.93 |
| 2025-11-21 | BDX | 192.69 | -18.1 | 559.9 | 14.93 |
| 2025-11-24 | BDX | 190.99 | -18.1 | 502.6 | 14.93 |
| 2025-11-25 | BDX | 195.49 | -18.1 | 576.5 | 14.93 |
| 2025-11-26 | BDX | 193.94 | -18.1 | 505.0 | 14.93 |
| 2025-12-01 | BDX | 191.86 | -18.1 | 501.8 | 14.93 |
| 2025-12-02 | BDX | 190.47 | -18.1 | 511.1 | 14.93 |
| 2025-12-03 | BDX | 193.57 | -18.1 | 563.7 | 14.93 |
| 2025-12-04 | BDX | 193.81 | -18.1 | 529.8 | 14.93 |
| 2025-12-05 | BDX | 193.96 | -18.0 | 529.3 | 14.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | BDX | 0.15 | 1.23 | 1.15 |
| 2025-11-11 | BDX | 0.15 | 1.23 | 1.15 |
| 2025-11-12 | BDX | 0.15 | 1.23 | 1.09 |
| 2025-11-13 | BDX | 0.15 | 1.23 | 1.09 |
| 2025-11-14 | BDX | 0.15 | 1.23 | 1.09 |
| 2025-11-17 | BDX | 0.16 | 1.45 | 1.09 |
| 2025-11-18 | BDX | 0.16 | 1.45 | 1.09 |
| 2025-11-19 | BDX | 0.16 | 1.45 | 1.09 |
| 2025-11-20 | BDX | 0.16 | 1.45 | 1.09 |
| 2025-11-21 | BDX | 0.16 | 1.45 | 1.09 |
| 2025-11-24 | BDX | 0.16 | 1.28 | 1.09 |
| 2025-11-25 | BDX | 0.16 | 1.28 | 1.09 |
| 2025-11-26 | BDX | 0.16 | 1.28 | 1.46 |
| 2025-12-01 | BDX | 0.17 | 1.38 | 1.47 |
| 2025-12-02 | BDX | 0.17 | 1.38 | 1.47 |
| 2025-12-03 | BDX | 0.43 | 1.38 | 1.47 |
| 2025-12-04 | BDX | 0.43 | 1.38 | 1.47 |
| 2025-12-05 | BDX | 0.36 | 1.38 | 1.47 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.96
Avg. EPS Est. Current Quarter
2.81
Avg. EPS Est. Next Quarter
3.37
Insider Transactions
0.36
Institutional Transactions
1.38
Beta
0.24
Average Sales Estimate Current Quarter
5150
Average Sales Estimate Next Quarter
5526
Fair Value
214.42
Quality Score
67
Growth Score
84
Sentiment Score
55
Actual DrawDown %
32.5
Max Drawdown 5-Year %
-40.1
Target Price
197.11
P/E
33.27
Forward P/E
12.27
PEG
7.17
P/S
2.53
P/B
2.18
P/Free Cash Flow
20.73
EPS
5.83
Average EPS Est. Cur. Y
14.94
EPS Next Y. (Est.)
15.91
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
7.68
Relative Volume
0.9
Return on Equity vs Sector %
-20.3
Return on Equity vs Industry %
-3.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.05
EBIT Estimation
529.3
Becton, Dickinson and CompanySector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 72000
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
stock quote shares BDX – Becton, Dickinson and Company Stock Price stock today
news today BDX – Becton, Dickinson and Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BDX – Becton, Dickinson and Company yahoo finance google finance
stock history BDX – Becton, Dickinson and Company invest stock market
stock prices BDX premarket after hours
ticker BDX fair value insiders trading